Spitzfaden v. Dow Corning Corp.

833 So. 2d 512, 2002 WL 31761420
CourtLouisiana Court of Appeal
DecidedDecember 4, 2002
Docket98-CA-1612
StatusPublished
Cited by2 cases

This text of 833 So. 2d 512 (Spitzfaden v. Dow Corning Corp.) is published on Counsel Stack Legal Research, covering Louisiana Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Spitzfaden v. Dow Corning Corp., 833 So. 2d 512, 2002 WL 31761420 (La. Ct. App. 2002).

Opinion

833 So.2d 512 (2002)

Marilyn SPITZFADEN, et al.
v.
DOW CORNING CORPORATION, Dow Corning Wright, et al.

No. 98-CA-1612.

Court of Appeal of Louisiana, Fourth Circuit.

December 4, 2002.
Rehearing Denied January 15, 2003.

*513 Richard L. Root, Betsy J. Barnes, Barnes & Root, L.L.C., New Orleans, LA, for Plaintiff/Appellee.

Charles M. Steen, Stephanie G. McShane, Steen, McShane & Williamson, L.L.C., New Orleans, LA, and John W. Donley, Kirkland & Ellis, Chicago, IL, and H. Alston Johnson, III, Phelps Dunbar, L.L.P., Rouge, LA, for Defendant/Appellant.

(Court composed of Judge JAMES F. McKAY III, Judge DENNIS R. BAGNERIS, SR., and Judge MICHAEL E. KIRBY.).

DENNIS R. BAGNERIS, SR., Judge.

Defendant Dow Chemical appeals the trial court's judgment, which found that, notwithstanding the decertification of the class, the Phase I verdict was binding on all absent former class members and the eight individual plaintiffs.

*514 FACTS AND PROCEDURAL HISTORY

On February 12, 1992, Mary Spitzfaden filed suit individually and as the putative representative of a class of claimants comprised of Louisiana residents who received silicone gel breast implants and of non-residents whose breast implant surgeries were performed in Louisiana. The petition named as defendants Dow Corning Corporation, Dow Corning Wright Corporation, and Southern Baptist Hospital.[1] On February 20, 1992, plaintiffs added as defendants McGhan Medical Corporation, Mentor Corporation, Bristol Myers Squibb Company, Surgitek, Inc., Baxter Health Care Corporation, Natural Surgical Specialties, Inc., Bioplasty Corporation, and Heyer-Schulte Corporation.

On March 3, 1992, plaintiffs filed a Second Supplemental and Amending Petition naming nine new plaintiffs and one Jane Doe as class representative. On March 4, 1992, the trial court certified a class action, a decision that this Court affirmed in May 1993.

On March 3, 1994, the plaintiffs filed a Third Supplemental and Amending Petition adding forty-eight defendants, including Dow Chemical, to this matter. The Third Supplemental and Amending Petition also expanded the class by adding recipients of saline and polyurethane implants, and dropping any requirement of injury or future injury as a condition of membership in the class. After filing this Third Supplemental and Amending Petition, plaintiffs' counsel neither requested certification of their expanded class nor certification of the claims against any of the forty-eight new defendants. On March 10, 1995, plaintiffs filed a Fourth Amended Petition, which added new parties and brought the total number of defendants to more than a hundred.

In May 1996, the trial court entered a Case Management Order scheduling a trial against defendant Dow Chemical for March 1997. On March 13, 1997, two weeks before trial, the trial court issued another Case Management Order, which divided the trial into four phases. The jury was to be dismissed after the trial of Phase II. The order called for common issues to be tried in Phase I, listing the following nine issues as to be tried in Phase I:

(1) Whether defendant, Dow Chemical, was negligent in its researching and testing of silicones.
(2) Whether defendant, Dow Chemical, was negligent in failing to adequately disclose the risks and dangers of using silicones in the human body.
(3) Whether defendant, Dow Chemical knowingly or intentionally kept silent about, concealed or suppressed information about the risks and dangers of using silicones in the human body.
(4) Whether the information was material.
(5) Whether defendant, Dow Chemical knowingly or intentionally made any false or misleading statements about the safety or quality of using silicone in the human body.
(6) Were the above statements material.
(7) Whether defendant, Dow Chemical intentionally or willfully conspired or acted in concert with Dow Corning in doing any wrongful act or omission in connection with using silicones in the human body.
(8) Whether defendant, Dow Chemical aid and abet any wrongful acts or omissions of Dow Corning in connection with using silicones in the human body.
*515 (9) Whether defendant Dow Chemical's conduct kept breast implant recipients from being able to make informed decisions about or giving their informed consent to the insertion of Dow Corning silicone breast implants into their bodies.

The order reserved causation and damage issues for Phase II, listing the following four issues as to be tried in Phase II:

(1) Did silicones cause the injuries complained of in these plaintiffs [the class representatives]?
(2) Were the plaintiffs aware of the risks and danger of silicone in the body?
(3) If plaintiffs had known of risks would they have had the implants?
(4) Whether individual class reps had damages?

The order then called for Class Notice in Phase III, and the adjudication of damages for class members in Phase IV.

On March 28, 1997, the trial commenced and was tried intermittently until August 14, 1997. On August 18, 1997, a jury verdict was returned, which consisted of affirmative answers to seven interrogatories:

1. Do you find that Dow Chemical did research and/or testing of silicone for human implantation for Dow Corning?
2. Was Dow Chemical negligent in the above referenced testing and/or research of silicone?
3. Did Dow Chemical knowingly or intentionally remain silent, conceal or suppress information about the harms and dangers of using silicone in the human body?
4. Was the probability of that type of harm a risk which reasonable women would consider in deciding to be implanted?
5. Did Dow Chemical knowingly or intentionally make any false or misleading statements about the safety or quality of using silicone in the human body?
6. Was/Were the statement(s) of the nature that a reasonable woman would consider in deciding to be implanted?
7. Did Dow Chemical intentionally or willfully conspire or act in concert with Dow Corning in doing any wrongful act or omission in connection with using silicone in the human body?

On September 25, 1997, less than a month after the jury verdict was returned, Dow Chemical filed a motion in the trial court for decertification of the class. On December 1, 1997, the trial judge signed a judgment, which granted Dow Chemical's motion for decertification. In the trial judge's reasons for decertifying the class action, she stated, in pertinent part:

There are simply too many individual issues due to the fact that members of the class were implanted with various types of breast implants, at different times in varying degrees and the implants have caused different diseases. Additionally, there are individual questions regarding each class members [sic] lifestyle and medical condition which are paramount to causation. The time period whereby the alleged torts were committed spans a thirty year period thus, requiring a different legal standard to be used for each plaintiff....
* * *

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Scott v. American Tobacco Co., Inc.
949 So. 2d 1266 (Louisiana Court of Appeal, 2007)
Doerr v. Mobil Oil Corp.
935 So. 2d 231 (Louisiana Court of Appeal, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
833 So. 2d 512, 2002 WL 31761420, Counsel Stack Legal Research, https://law.counselstack.com/opinion/spitzfaden-v-dow-corning-corp-lactapp-2002.